1. 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. (25th November 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J-F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 186PPhase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients. (25th November 2018) Authors: Ryoo, B-Y; Ren, Z; Kim, T-Y; Pan, H; Rau, K-M; Choi, H J; Park, J-W; Kim, J H; Yen, C-J; Kim, B-H; Zhou, D; Straub, J; Zhao, C; Qin, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 477OTepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. (24th November 2019) Authors: Park, K; Zhou, J; Kim, D-W; Ahmad, A R; Soo, R A; Bruns, R; Straub, J; Johne, A; Scheele, J; Yang, J C-H; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 487PPatient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study. (23rd October 2018) Authors: Laeufle, R; Arnold, D; Kopetz, S; Straub, J; Bruns, R; Massimini, G; Debenedetto, R; Linke, R; Elez Fernandez, E; Tabernero, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 493OTepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data. (25th November 2018) Authors: Sakai, H; Felip, E; Cortot, A B; Veillon, R; Griesinger, F; Patel, J; Horn, L; Mazieres, J; De Castro Carpeno, J; Morise, M; Sakamoto, T; Bruns, R; Scheele, J; Straub, J; Paik, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 536TiPINSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study. (24th November 2019) Authors: Yang, J C-H; Ellers-Lenz, B; Straub, J; Johne, A; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 546TiPTepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress. (25th November 2018) Authors: Paik, P; Sakai, H; Bruns, R; Scheele, J; Straub, J; Felip, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 621PDPhase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Ryoo, B-Y; Ren, Z; Kim, T-Y; Pan, H; Rau, K-M; Choi, H J; Park, J-W; Kim, J H; Yen, C-J; Kim, B-H; Zhou, D; Straub, J; Zhao, C; Qin, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 62OTepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. (24th November 2019) Authors: Park, K; Felip, E; Veillon, R; Cortot, A; Mazieres, J; Sakai, H; Reinmuth, N; Viteri, S; Chen, Y-M; Han, J-Y; Jang, T-W; Morise, M; Sakamoto, T; Tokito, T; Cho, B C; Bruns, R; Scheele, J; Straub, J; Le, X; Paik, P K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 698PPhase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗